Results 181 to 190 of about 126,336 (274)

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter   +20 more
wiley   +1 more source

Structural Basis for Trivalent Cross‐Linking of a Patient‐Derived IgE Antibody by the Major Peanut Allergen Ara h 2.0201

open access: yesAllergy, EarlyView.
Graphical The crystal structure of a major peanut allergen Ara h 2.0201 in a complex with a human‐derived IgE Fab fragment has been determined. The immunocomplex shows the trivalent binding of Fabs, creating a cross‐linked structure effective in the formation of large complexes on the surface of effector cells. Hydroxylation of proline has implications
Tarja Parkkinen   +4 more
wiley   +1 more source

A One‐Strength Dose Escalation Regimen for Birch Pollen SCIT Is Safe and Tolerable in Children, Adolescents, and Adults

open access: yesAllergy, EarlyView.
This study evaluated safety and tolerability of birch pollen SCIT during dose escalation with a new One‐Strength regimen (3 injections, Strength B) compared to the Standard regimen (7 injections, Strengths A and B) in patients aged 5–65 years. Safety and tolerability were comparable between the two regimens in adults, adolescents, and adolescents, as ...
Marek Jutel   +5 more
wiley   +1 more source

A Proteomics Outlook on the Molecular Effectors of CAR-T Cell Therapy in Cancer Management. [PDF]

open access: yesJ Proteome Res
Teibo JO   +3 more
europepmc   +1 more source

Nail Dystrophy Treated With Marigold Therapy in a Patient With Epidermolysis Bullosa Simplex

open access: yes
Australasian Journal of Dermatology, EarlyView.
Aalia Syed   +2 more
wiley   +1 more source

Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study

open access: yesAllergy, EarlyView.
Evaluation en vie Réelle de l'Allergo‐Prescription en Pratique (ERAPP) is a large, prospective, real‐world cohort of children and adults initiating named‐patient product sublingual immunotherapy (NPP‐SLIT) in France. More than 80% of patients reported a clinically meaningful, expectation‐anchored benefit (Patient Benefit Index ≥ 1) at 12–15 months. The
Davide Caimmi   +9 more
wiley   +1 more source

Enhanced recovery following neck of femur fractures - improving outcomes : a survey of current perioperative practice. [PDF]

open access: yesBone Jt Open
See A   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy